Literature DB >> 16958643

Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.

D R Williams1.   

Abstract

The majority of neurodegenerative diseases are characterized by the deposition of insoluble protein in cells of the neuromuscular system. Advances in molecular neuropathology have allowed a classification system of neurodegenerative diseases based on this protein accumulation. Microtubule-associated tau is one protein that has important functions in healthy neurons, but forms insoluble deposits in diseases now known collectively as tauopathies. Tauopathies encompass more than 20 clinicopathological entities, including Alzheimer's disease, the most common tauopathy, progressive supranuclear palsy, Pick's disease, corticobasal degeneration and post-encephalitic parkinsonism. There are important clinical, pathological, biochemical and genetic similarities in the range of these diseases and they have helped to advance our understanding of the aetiological factors that initiate neurodegeneration and tau accumulation. This review examines the important clinical features of the most prevalent tauopathies and the molecular and pathological features that underpin the classification system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16958643     DOI: 10.1111/j.1445-5994.2006.01153.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  71 in total

1.  HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.

Authors:  Julia Elisa Sepulveda-Diaz; Seyedeh Maryam Alavi Naini; Minh Bao Huynh; Mohand Ouidir Ouidja; Constantin Yanicostas; Sandrine Chantepie; Joao Villares; Foudil Lamari; Estelle Jospin; Toin H van Kuppevelt; Ayikoe Guy Mensah-Nyagan; Rita Raisman-Vozari; Nadia Soussi-Yanicostas; Dulce Papy-Garcia
Journal:  Brain       Date:  2015-04-04       Impact factor: 13.501

2.  Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17.

Authors:  Aidan Kenny; Félix Hernández; Jesús Avila; José J Lucas; David C Henshall; Jochen Hm Prehn; Eva M Jiménez-Mateos; Tobias Engel
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-12-25

3.  Loss of Hsp110 leads to age-dependent tau hyperphosphorylation and early accumulation of insoluble amyloid beta.

Authors:  Binnur Eroglu; Demetrius Moskophidis; Nahid F Mivechi
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

4.  Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.

Authors:  Joana R F Santos; Chris Bauer; Johannes Schuchhardt; Dirk Wedekind; Katharina Waniek; Ingolf Lachmann; Jens Wiltfang; Jonathan Vogelgsang
Journal:  J Neural Transm (Vienna)       Date:  2019-02-14       Impact factor: 3.575

Review 5.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

Review 6.  Recent trends in mucopolysaccharidosis research.

Authors:  Hiroshi Kobayashi
Journal:  J Hum Genet       Date:  2018-11-19       Impact factor: 3.172

Review 7.  Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.

Authors:  Keshav Anand; Marwan Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2015-08-01       Impact factor: 6.206

8.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

9.  Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease.

Authors:  Peter T Nelson; Erin L Abner; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Karen Santacruz; Charles D Smith; Ela Patel; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2009-07       Impact factor: 3.685

10.  Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.